# Commission Implementing Directive 2012/52/EU of 20 December 2012 laying down measures to facilitate the recognition of medical prescriptions issued in another Member State (Text with EEA relevance), Division: Identification of the prescribed product, where applicable

Extent: E+W+S+N.I.

‘Common name’ as defined by Article 1 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
The brand name if:
(a) the prescribed product is a biological medicinal product, as defined in point 3.2.1.1.(b) of Annex I (Part I) to Directive 2001/83; or
(b) the prescribing health professional deems it medically necessary; in that case the prescription shall shortly state the reasons justifying the use of the brand name
Pharmaceutical formulation (tablet, solution, etc.)
Quantity
Strength, as defined in Article 1 of Directive 2001/83/EC
Dosage regimen

---
Source: https://www.legislation.gov.uk/eudr/2012/52/annex/division/1/division/4 (the official version)
Page: https://openlegislation.uk/eu-directive-2012-52/annex/division-1/division-4
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.